Endra Life Sciences
NDRA
Endra Life Sciences (NDRA) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Ascendiant Capital | Maintained | Buy | $25.00 from $27.00 | Jun 1, 2026 |
| Ascendiant Capital | Maintained | Buy | $30.00 from $38.00 | Dec 8, 2025 |
| Ascendiant Capital | Maintained | Buy | $38.00 from $46.00 | Sep 22, 2025 |
| Ascendiant Capital | Maintained | Buy | $46.00 from $50.00 | May 30, 2025 |
| Ascendiant Capital | Maintained | Buy | $50.00 from $75.00 | Apr 21, 2025 |
| Ascendiant Capital | Maintained | Buy | $8.00 from $10.00 | Jun 7, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $9.00 from $100.00 | Mar 31, 2023 |
Frequently asked questions
What is the latest analyst rating on NDRA?
On Jun 1, 2026, Ascendiant Capital maintained Endra Life Sciences at Buy with a price target of $25.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.